Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Living donor liver transplantation

Song, Gi-Won; Lee, Sung-Gyu

Current Opinion in Organ Transplantation: June 2014 - Volume 19 - Issue 3 - p 217–222
doi: 10.1097/MOT.0000000000000088
LIVER TRANSPLANTATION: Edited by Jan P. Lerut
Buy

Purpose of review Living donor liver transplantation (LDLT) continues to evolve, generating interesting issues on the applicability and safety of new techniques.

Recent findings Specific selection criteria and standardized surgical techniques with high ethical and medical standards are needed to minimize donor risk. In this aspect, minimally invasive donor hepatectomy has caused controversies. The reproducibility and safety of pure laparoscopic major hepatectomy in LDLT remains uncertain. Therefore, a stepwise approach is needed to avoid unnecessary donor risk. To expand the living donor pool, dual graft and ABO-incompatible LDLT have emerged as well tolerated and effective methods. The extended selection criteria for hepatocellular carcinoma in LDLT appear acceptable to balance donor risk and recipient outcome. However, these criteria should be validated based on the risk–benefit ratio. Despite technical advances, technical challenges persist such as Budd–Chiari syndrome and portal vein thrombosis. To address these issues, several innovative surgical techniques have been proposed and have shown promising results.

Summary LDLT is associated with donor safety concerns, technical complexity, and small-for-size issues. Nonetheless, accumulated experience and technical know-how from large-volume Asian LDLT centers have led to progress in LDLT. Further technical refinement and investigation to overcome the disadvantages of partial grafts will broaden the applicability of LDLT.

Division of Hepatobiliary Surgery and Liver Transplantation, Department of Surgery, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea

Correspondence to Sung-Gyu Lee, MD, PhD, FACS, 88 Olympic-Ro, 43-Gil, Songpa-Gu, Seoul 138-736, Korea. Tel: +82 2 3010 3485; fax: +82 2 474 9027; e-mail: sglee2@amc.seoul.kr

© 2014 Wolters Kluwer Health | Lippincott Williams & Wilkins